Active Ingredient History
Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD). It is used in form of chewable tablets. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Kidney Injury (Phase 2)
Anemia (Phase 4)
Anemia, Iron-Deficiency (Phase 4)
Aortic Valve Stenosis (Phase 4)
Arthropathy, Neurogenic (Phase 2)
Asthma (Phase 4)
Bariatric Surgery (Phase 4)
Blood Loss, Surgical (Phase 4)
Colitis, Ulcerative (Phase 3)
Colorectal Neoplasms (Phase 4)
Critical Illness (Phase 2)
Crohn Disease (Phase 3)
Delivery, Obstetric (Phase 4)
Dialysis (Phase 4)
Endometrial Neoplasms (Phase 4)
Fatigue (Phase 3)
Fractures, Bone (Phase 4)
Gastric Bypass (Phase 4)
General Surgery (Phase 4)
Hamartoma (Phase 4)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 1/Phase 2)
Heart Failure (Phase 4)
Hematologic Neoplasms (Phase 2/Phase 3)
Hip Fractures (Phase 4)
Hyperphosphatemia (Phase 4)
Hypertension, Pulmonary (Phase 2)
Hypoalbuminemia (Phase 4)
Infant, Premature, Diseases (Phase 2)
Inflammatory Bowel Diseases (Phase 4)
Iron Deficiencies (Phase 4)
Iron Overload (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Lymphoma (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoproliferative Disorders (Phase 3)
Malnutrition (Phase 4)
Multiple Myeloma (Phase 3)
Neoplasms (Phase 3)
Osteoarthritis (Phase 4)
Precancerous Conditions (Phase 3)
Pregnancy (Phase 2)
Pregnancy Complications (Phase 4)
Preoperative Exercise (Phase 4)
Puerperal Disorders (Phase 4)
Renal Dialysis (Phase 4)
Renal Insufficiency (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Restless Legs Syndrome (Phase 2)
Weight Loss (Phase 3)
Wounds and Injuries (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue